首页> 外文期刊>Journal of pediatric gastroenterology and nutrition >Discordant Erythrocyte Sedimentation Rate and C-reactive Protein in Children With Inflammatory Bowel Disease Taking Azathioprine or 6-Mercaptopurine.
【24h】

Discordant Erythrocyte Sedimentation Rate and C-reactive Protein in Children With Inflammatory Bowel Disease Taking Azathioprine or 6-Mercaptopurine.

机译:服用硫唑嘌呤或6-巯基嘌呤的炎性肠病患儿的红细胞沉降速率和C反应蛋白不一致。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND:: Inflammatory bowel disease (IBD) is characterized by periods of relapse and remission. Treatment is aimed at reducing symptoms during relapse and prolonging the duration of remissions. 6-Mercaptopurine (6-MP) and its prodrug azathioprine (AZA) are commonly used to prolong clinical remissions. The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are two widely used laboratory markers of inflammation. The authors observed an unexplained discordance between ESR and CRP in children with asymptomatic IBD who were being treated with AZA or 6-MP. OBJECTIVE:: To characterize children with IBD in remission treated with 6-MP or AZA who have persistently elevated ESR but normal CRP. METHODS:: All patients seen in Pediatric Gastroenterology Clinic between January 1, 1995, and December 31, 2002, with Crohn disease or ulcerative colitis who received AZA or 6-MP continuously for at least 6 months were identified and their medical records reviewed. RESULTS:: One hundred twenty patients met the eligibility criteria. Twelve had an ESR >18 mm/hour on at least three occasions during at least 12 consecutive months with a simultaneous CRP <0.8 mg/dL. Eleven of these 12 had no signs or symptoms of active disease and had Pediatric Crohn Disease Activity Index scores <10 for at least 12 consecutive months while the ESR was elevated. Disease duration was similar in the 11 children with asymptomatic disease and with discordant ESR and CRP and in 108 children with concordant ESR and CRP (69.2 + 22.5 months v 54.3 +/- 40.1 months, P = 0.0709). Duration of AZA or 6-MP therapy was greater in the 11 children with asymptomatic disease and discordant ESR and CRP than in those with or without symptoms and with concordant ESR and CRP (58.1 +/- 16.4 months v 36.6 +/- 24.1 months, P = 0.0043). There were no differences between the groups with respect to diagnosis, location of disease, or age at onset of symptoms. The mean corpuscular volume (MCV) was somewhat larger in the children with discordant ESR and CRP than in the children with concordant ESR and CRP (91.4 +/- 6.97 fL v 87.0 +/- 7.07 fL, respectively, P = 0.0373); however, in both groups, the MCV was in the normal range. There were no significant differences in hematocrit, white blood cell count, serum albumin, total serum protein, or estimated serum globulin between the groups. CONCLUSIONS:: The results suggest that among children treated with AZA or 6-MP, CRP may be a more reliable indirect indicator of inflammation than ESR. This report alerts clinicians that some children taking AZA or 6-MP may have persistent elevation of the ESR with a normal CRP and have no clinical evidence of active disease.
机译:背景:炎症性肠病(IBD)的特点是复发和缓解期。治疗旨在减轻复发期间的症状并延长缓解时间。 6-巯基嘌呤(6-MP)及其前药硫唑嘌呤(AZA)通常用于延长临床缓解期。红细胞沉降率(ESR)和C反应蛋白(CRP)是炎症的两个广泛使用的实验室指标。作者观察到在接受AZA或6-MP治疗的无症状IBD儿童中ESR和CRP之间存在无法解释的不一致。目的:表征ESP持续升高但CRP正常的6-MP或AZA治疗缓解的IBD患儿。方法:确定1995年1月1日至2002年12月31日在小儿消化内科门诊就诊的所有克罗恩病或溃疡性结肠炎患者,他们连续至少6个月连续接受AZA或6-MP治疗,并对其医疗记录进行了回顾。结果:120名患者符合入选标准。在连续至少12个月内,至少有12次ESR至少有3次超过18 mm /小时,同时CRP <0.8 mg / dL。这12个中有11个没有活动性疾病的体征或症状,并且在ESR升高的同时,至少连续12个月小儿克罗恩病活动指数得分<10。 11例无症状,ESR和CRP不一致的儿童和108例ESR和CRP一致的儿童的病程相似(69.2 + 22.5个月v 54.3 +/- 40.1个月,P = 0.0709)。 11例无症状疾病,ESR和CRP不一致的儿童的AZA或6-MP治疗的持续时间长于有症状或无症状,ESR和CRP一致的儿童(58.1 +/- 16.4个月v 36.6 +/- 24.1个月, P = 0.0043)。两组之间在诊断,疾病位置或症状发作年龄方面没有差异。 ESR和CRP不一致的患儿的平均红细胞体积(MCV)比ESR和CRP一致的患儿的平均红细胞体积要大一些(分别为91.4 +/- 6.97 fL v 87.0 +/- 7.07 fL,P = 0.0373);然而,两组的MCV均在正常范围内。两组之间的血细胞比容,白细胞计数,血清白蛋白,总血清蛋白或估计的血清球蛋白无显着差异。结论:结果表明,在接受AZA或6-MP治疗的儿童中,CRP可能是比ESR更可靠的间接炎症指标。该报告提醒临床医生,一些服用AZA或6-MP的儿童可能具有持续的CRP且ESR持续升高,并且没有活动性疾病的临床证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号